Alnylam Pharmaceuticals (NASDAQ:ALNY) Receives Buy Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) in a research report report published on Monday morning, Benzinga reports. The firm currently has a $405.00 price objective on the biopharmaceutical company’s stock.

Several other equities analysts also recently issued reports on ALNY. Stifel Nicolaus reissued a buy rating and set a $240.00 price target on shares of Alnylam Pharmaceuticals in a report on Thursday, September 14th. StockNews.com assumed coverage on shares of Alnylam Pharmaceuticals in a report on Thursday, August 17th. They set a hold rating for the company. William Blair reaffirmed an outperform rating on shares of Alnylam Pharmaceuticals in a report on Tuesday, July 25th. Morgan Stanley reaffirmed an equal weight rating and issued a $210.00 price objective on shares of Alnylam Pharmaceuticals in a report on Friday, August 4th. Finally, Royal Bank of Canada reaffirmed an outperform rating and issued a $270.00 price objective on shares of Alnylam Pharmaceuticals in a report on Tuesday, September 12th. Six investment analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company. According to MarketBeat, Alnylam Pharmaceuticals presently has an average rating of Moderate Buy and an average price target of $247.40.

Alnylam Pharmaceuticals Stock Performance

ALNY opened at $179.77 on Monday. Alnylam Pharmaceuticals has a 1 year low of $178.21 and a 1 year high of $242.97. The company’s 50 day simple moving average is $194.05 and its 200 day simple moving average is $195.50. The stock has a market capitalization of $22.47 billion, a PE ratio of -20.88 and a beta of 0.45.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported ($2.21) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.72) by ($0.49). The firm had revenue of $318.75 million for the quarter, compared to analysts’ expectations of $331.73 million. Alnylam Pharmaceuticals had a negative net margin of 85.95% and a negative return on equity of 1,287.80%. As a group, sell-side analysts expect that Alnylam Pharmaceuticals will post -6.79 earnings per share for the current fiscal year.

Insider Buying and Selling at Alnylam Pharmaceuticals

In related news, CMO Pushkal Garg sold 3,461 shares of the business’s stock in a transaction that occurred on Friday, August 4th. The stock was sold at an average price of $185.85, for a total value of $643,226.85. Following the completion of the sale, the chief marketing officer now owns 8,511 shares in the company, valued at approximately $1,581,769.35. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other news, CFO Jeffrey V. Poulton sold 3,460 shares of Alnylam Pharmaceuticals stock in a transaction on Friday, August 4th. The shares were sold at an average price of $185.85, for a total transaction of $643,041.00. Following the transaction, the chief financial officer now owns 15,873 shares in the company, valued at approximately $2,949,997.05. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CMO Pushkal Garg sold 3,461 shares of the company’s stock in a transaction on Friday, August 4th. The stock was sold at an average price of $185.85, for a total transaction of $643,226.85. Following the transaction, the chief marketing officer now owns 8,511 shares of the company’s stock, valued at approximately $1,581,769.35. The disclosure for this sale can be found here. Insiders sold 15,144 shares of company stock valued at $2,806,347 in the last quarter. 1.40% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Belpointe Asset Management LLC acquired a new stake in Alnylam Pharmaceuticals in the 4th quarter valued at $25,000. Capital Advisors Ltd. LLC boosted its holdings in shares of Alnylam Pharmaceuticals by 1,480.0% in the second quarter. Capital Advisors Ltd. LLC now owns 158 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 148 shares during the period. KB Financial Partners LLC purchased a new stake in shares of Alnylam Pharmaceuticals during the first quarter worth approximately $35,000. Archer Investment Corp purchased a new stake in shares of Alnylam Pharmaceuticals during the first quarter worth approximately $40,000. Finally, V Square Quantitative Management LLC purchased a new position in Alnylam Pharmaceuticals in the second quarter worth $53,000. 93.98% of the stock is currently owned by institutional investors.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases.